Carole Decker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carole Decker has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
John A. Spertus
From the School of Nursing (C.D.) and Department of Biomedical and Health Informatics, School of Medicine (J.A.S.), University of Missouri-Kansas City; Cardiovascular Outcomes Research, Saint Luke’s Hospital of Kansas City (C.D., E.C., E.G., B.G., D.S., J.A.S.); Department of Neurology, Geffen School of Medicine at UCLA (M.E.Q., E.C.) and UCLA Comprehensive Stroke Center (J.L.S.); Center for Advanced Brain and Neurological Care, University of Kansas Hospital (M.R.); US Medical Affairs,...
7 shared publicationsBrian Garavalia
From the School of Nursing (C.D.) and Department of Biomedical and Health Informatics, School of Medicine (J.A.S.), University of Missouri-Kansas City; Cardiovascular Outcomes Research, Saint Luke’s Hospital of Kansas City (C.D., E.C., E.G., B.G., D.S., J.A.S.); Department of Neurology, Geffen School of Medicine at UCLA (M.E.Q., E.C.) and UCLA Comprehensive Stroke Center (J.L.S.); Center for Advanced Brain and Neurological Care, University of Kansas Hospital (M.R.); US Medical Affairs,...
6 shared publicationsLinda Garavalia
University of Missouri-Kansas City School of Pharmacy, Kansas City, MO
6 shared publicationsDonna M. Buchanan
Carole Decker, PhD, RN Researcher/Outcomes Manager, Mid America Heart Institute at Saint Luke's Hospital; Adjunct Faculty, University of Missouri-Kansas City School of Nursing
2 shared publicationsJohn A Spertus
Mid America Heart Institute at Saint Luke’s Hospital in Kansas City Missouri, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA
2 shared publicationsAmy Ba Shipman
Carole Decker, PhD, RN Researcher/Outcomes Manager, Mid America Heart Institute at Saint Luke's Hospital; Adjunct Faculty, University of Missouri-Kansas City School of Nursing
1 shared publication
Latest Publications
- 1 October 2015
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 8 (6_suppl_3) , S109-S116
Patient-Centered Decision Support in Acute Ischemic Stroke
Background—National guidelines endorse recombinant tissue-type plasminogen activator (r-tPA) in eligible patients with acute ischemic stroke to improve patients’ functional recovery. However, 23% to 40% of ideal candidates with acute ischemic stroke for reperfusion are not treated, perhaps because of the difficulty in explaining the benefits and risks of r-tPA within the frenetic pace of emergency department care. To support better knowledge transfer and creation of a shared decision-making tool, we conducted qualitative interviews to define the information needs and preferred presentation format for stroke survivors, caregivers, and clinicians considering r-tPA treatment. Methods and Results—A multidisciplinary team used qualitative research methods to identify informational needs and strategies for describing the benefits and risks of r-tPA in a clinical setting. Through focus groups (n=10) of stroke survivors (n=39) and caregivers (n=24) and individual interviews with emergency physicians (n=23) and advanced practice nurses (n=20), several themes emerged. Survivors and caregivers preferred a broader definition of a good outcome (independence, rather than no significant disability), simpler graphs as compared with detailed pictographs, and presentation of both population and individualized benefits (framed positively) and risk of receiving r-tPA. Some physicians expressed skepticism with the data and the ability to present risk/benefit information emergently, whereas other physicians and most advanced practice nurses thought such information would improve care. Physicians stressed the importance of presenting the risk of thrombolytic-related intracranial hemorrhage. Conclusions—This study suggests that a positively framed risk–benefit tool with graphical presentations of general and patient-specific risk estimates could support patients and providers in considering r-tPA for acute ischemic stroke. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01864928.
- 1 October 2015
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 8 (6_suppl_3) , S109-S116
Patient-Centered Decision Support in Acute Ischemic Stroke
Background—National guidelines endorse recombinant tissue-type plasminogen activator (r-tPA) in eligible patients with acute ischemic stroke to improve patients’ functional recovery. However, 23% to 40% of ideal candidates with acute ischemic stroke for reperfusion are not treated, perhaps because of the difficulty in explaining the benefits and risks of r-tPA within the frenetic pace of emergency department care. To support better knowledge transfer and creation of a shared decision-making tool, we conducted qualitative interviews to define the information needs and preferred presentation format for stroke survivors, caregivers, and clinicians considering r-tPA treatment. Methods and Results—A multidisciplinary team used qualitative research methods to identify informational needs and strategies for describing the benefits and risks of r-tPA in a clinical setting. Through focus groups (n=10) of stroke survivors (n=39) and caregivers (n=24) and individual interviews with emergency physicians (n=23) and advanced practice nurses (n=20), several themes emerged. Survivors and caregivers preferred a broader definition of a good outcome (independence, rather than no significant disability), simpler graphs as compared with detailed pictographs, and presentation of both population and individualized benefits (framed positively) and risk of receiving r-tPA. Some physicians expressed skepticism with the data and the ability to present risk/benefit information emergently, whereas other physicians and most advanced practice nurses thought such information would improve care. Physicians stressed the importance of presenting the risk of thrombolytic-related intracranial hemorrhage. Conclusions—This study suggests that a positively framed risk–benefit tool with graphical presentations of general and patient-specific risk estimates could support patients and providers in considering r-tPA for acute ischemic stroke. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01864928.
- Open Access
- 1 June 2012
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. 5, 129-135
Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians
Background: Warfarin, the most commonly used antithrombotic agent for stroke prophylaxis in atrial fibrillation (AF), requires regular monitoring, frequent dosage adjustments, and dietary restrictions. Clinicians' perceptions of barriers to optimal AF management are an important factor in treatment. Anticoagulation management for AF is overseen by both cardiology and internal medicine (IM) practices. Thus, gaining the perspective of specialists and generalists is essential in understanding barriers to treatment. We used qualitative research methods to define key issues in the prescription of warfarin therapy for AF by cardiology specialists and IM physicians. Methods and results: Clinicians were interviewed to identify barriers to warfarin treatment in a large Midwestern city. Interviews were conducted until thematic saturation occurred. Content analysis yielded several themes. The most salient theme that emerged from clinician interviews was use of characteristics other than the patient's CHADS2 score to enact a treatment plan, such as the patient's social situation and past medication-taking behavior. Other themes included patient knowledge, real-world problems, breakdown in communication, and clinician reluctance. Conclusion: Warfarin treatment is associated with many challenges. The barriers identified by clinicians highlight the unmet need associated with stroke prophylaxis in AF and the opportunity to improve anticoagulation treatment in AF. Social and lifestyle factors were important considerations in determining treatment.
- 1 June 2012
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. 5, 129-135
Open AccessExploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians
Background: Warfarin, the most commonly used antithrombotic agent for stroke prophylaxis in atrial fibrillation (AF), requires regular monitoring, frequent dosage adjustments, and dietary restrictions. Clinicians' perceptions of barriers to optimal AF management are an important factor in treatment. Anticoagulation management for AF is overseen by both cardiology and internal medicine (IM) practices. Thus, gaining the perspective of specialists and generalists is essential in understanding barriers to treatment. We used qualitative research methods to define key issues in the prescription of warfarin therapy for AF by cardiology specialists and IM physicians. Methods and results: Clinicians were interviewed to identify barriers to warfarin treatment in a large Midwestern city. Interviews were conducted until thematic saturation occurred. Content analysis yielded several themes. The most salient theme that emerged from clinician interviews was use of characteristics other than the patient's CHADS2 score to enact a treatment plan, such as the patient's social situation and past medication-taking behavior. Other themes included patient knowledge, real-world problems, breakdown in communication, and clinician reluctance. Conclusion: Warfarin treatment is associated with many challenges. The barriers identified by clinicians highlight the unmet need associated with stroke prophylaxis in AF and the opportunity to improve anticoagulation treatment in AF. Social and lifestyle factors were important considerations in determining treatment.
- 1 July 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 26 (4) , E12-E19
Medication Discussion Questions (MedDQ)
Background and Research Objective: Adherence to evidence-based therapies has emerged as one of the great challenges of translating discoveries to clinical care to optimize patient outcomes. In particular, nonadherence to lifesaving medications continues to trouble health care systems. We conducted a series of studies to investigate why cardiac patients stop life-sustaining medications and to develop a tool to proactively address medication adherence issues. We could find no available preventive tools for communicating with patients about their medications in the clinical setting. In this article, we summarize the process of developing such a tool. Subjects and Methods: We used a mixed-methods approach in a series of studies that included examining quantitative data from a large patient registry, conducting in-depth qualitative patient interviews, creating items representative of the qualitative findings, pilot testing items with heart patients, surveying an expert panel to establish content validity, and conducting in-depth interviews with health care providers to assess implementation opportunities. Results and Conclusions: Patient interviews revealed that patients' values and beliefs, barriers to treatment, and prior medication-taking behavior were of primary importance in understanding medication discontinuance. Pilot testing, expert panel review, and an implementation feasibility evaluation resulted in an 11-item communication guide to be used in a variety of health care settings. Clinicians need an efficient way of systematically communicating with patients about heart medications to identify barriers and to initiate preventive interventions when patients report barriers or challenges to medication adherence.
- 1 July 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 26 (4) , E12-E19
Medication Discussion Questions (MedDQ)
Background and Research Objective: Adherence to evidence-based therapies has emerged as one of the great challenges of translating discoveries to clinical care to optimize patient outcomes. In particular, nonadherence to lifesaving medications continues to trouble health care systems. We conducted a series of studies to investigate why cardiac patients stop life-sustaining medications and to develop a tool to proactively address medication adherence issues. We could find no available preventive tools for communicating with patients about their medications in the clinical setting. In this article, we summarize the process of developing such a tool. Subjects and Methods: We used a mixed-methods approach in a series of studies that included examining quantitative data from a large patient registry, conducting in-depth qualitative patient interviews, creating items representative of the qualitative findings, pilot testing items with heart patients, surveying an expert panel to establish content validity, and conducting in-depth interviews with health care providers to assess implementation opportunities. Results and Conclusions: Patient interviews revealed that patients' values and beliefs, barriers to treatment, and prior medication-taking behavior were of primary importance in understanding medication discontinuance. Pilot testing, expert panel review, and an implementation feasibility evaluation resulted in an 11-item communication guide to be used in a variety of health care settings. Clinicians need an efficient way of systematically communicating with patients about heart medications to identify barriers and to initiate preventive interventions when patients report barriers or challenges to medication adherence.
- 1 March 2011
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 10 (1) , 50-55
Clinician–Patient Discord: Exploring Differences in Perspectives for Discontinuing Clopidogrel
Premature stopping of anti-platelet therapy has potentially fatal consequences for myocardial infarction (MI) patients who have received a drug-eluting stent (DES). Exploring multiple perspectives to identify contributing factors to the problem is essential. We gained patient and clinician perspectives as to why MI patients prematurely stop anti-platelet therapy (clopidogrel) after DES implantation. This qualitative, descriptive study of DES-treated MI patients (n=22) and of clinicians (physicians and nurse practitioners; n=17) from multiple U.S. cities used content analysis of interview data. Findings across patients and clinicians were then compared to examine congruent and contrasting reasons for premature clopidogrel discontinuance. Patients frequently identified communication and education (e.g. unaware they should be taking clopidogrel, unaware of intended duration of therapy) as the primary reasons for having stopped. Patients rarely cited cost, while clinicians most commonly cited cost as a reason for premature stopping. The discrepancy in perceptions of patients and clinicians as to the primary reason for early discontinuance suggests an important opportunity for improving persistence. Rather than focusing on the high costs of medications, something outside of their control, physicians should consider communicating more effectively the importance and intended duration of clopidogrel to their patients.
- 1 March 2011
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 10 (1) , 50-55
Clinician–Patient Discord: Exploring Differences in Perspectives for Discontinuing Clopidogrel
Premature stopping of anti-platelet therapy has potentially fatal consequences for myocardial infarction (MI) patients who have received a drug-eluting stent (DES). Exploring multiple perspectives to identify contributing factors to the problem is essential. We gained patient and clinician perspectives as to why MI patients prematurely stop anti-platelet therapy (clopidogrel) after DES implantation. This qualitative, descriptive study of DES-treated MI patients (n=22) and of clinicians (physicians and nurse practitioners; n=17) from multiple U.S. cities used content analysis of interview data. Findings across patients and clinicians were then compared to examine congruent and contrasting reasons for premature clopidogrel discontinuance. Patients frequently identified communication and education (e.g. unaware they should be taking clopidogrel, unaware of intended duration of therapy) as the primary reasons for having stopped. Patients rarely cited cost, while clinicians most commonly cited cost as a reason for premature stopping. The discrepancy in perceptions of patients and clinicians as to the primary reason for early discontinuance suggests an important opportunity for improving persistence. Rather than focusing on the high costs of medications, something outside of their control, physicians should consider communicating more effectively the importance and intended duration of clopidogrel to their patients.
- 1 September 2009
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 24 (5) , 371-379
Exploring Patients' Reasons for Discontinuance of Heart Medications
Background: Despite the importance of secondary prevention, nonadherence rates for patients with myocardial infarction (MI) range from 13% to 60% for prescribed, evidence-based medicines. Although rates and consequences of discontinuance vary for different medications, the existing literature provides little insight into reasons for discontinuance. Objective: To address this gap, we explored clopidogrel and cholesterol-lowering therapy (CLT) discontinuance after an MI to understand patients' reasons for stopping these 2 medications. Methods: In this qualitative descriptive study, 2 groups of patients who stopped a heart medication-either clopidogrel or CLT-were recruited from a prospective MI registry. Patients who discontinued CLT (n = 29) or clopidogrel (n = 11) were interviewed within 18 months of hospitalization. Patients were recruited and interviewed until data saturation was achieved. The Health Belief Model was used as an organizing framework in analyzing and coding the narrative data. The codes were then summarized for each group and compared to identify similarities and differences in reasons for CLT and clopidogrel discontinuance. Results and Conclusions: The most common reason for CLT discontinuance was adverse effects that were painful and interfered with daily life. Less common reasons for discontinuance were prescription confusion, cost, mistrust in medicines/healthcare system, and preference for alternative therapies. Reasons for clopidogrel discontinuance were duration confusion, adverse effects, and cost. Although doctors stopped patients' clopidogrel in preparation for surgery, doctors conceded to discontinuance of CLT for patients who experienced adverse effects after trying 2 to 3 different CLTs. Patients who discontinued CLT were more likely to believe that they did not need the treatment than do patients who discontinued clopidogrel. Clinicians should be aware that reasons may vary across patients and medication class for prematurely stopping therapy; thus, proactive interventions should be targeted to address these differences. Identifying at-risk patients for targeted interventions to prevent premature cardiac medication discontinuation is vital.
- 1 September 2009
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 24 (5) , 371-379
Exploring Patients' Reasons for Discontinuance of Heart Medications
Background: Despite the importance of secondary prevention, nonadherence rates for patients with myocardial infarction (MI) range from 13% to 60% for prescribed, evidence-based medicines. Although rates and consequences of discontinuance vary for different medications, the existing literature provides little insight into reasons for discontinuance. Objective: To address this gap, we explored clopidogrel and cholesterol-lowering therapy (CLT) discontinuance after an MI to understand patients' reasons for stopping these 2 medications. Methods: In this qualitative descriptive study, 2 groups of patients who stopped a heart medication-either clopidogrel or CLT-were recruited from a prospective MI registry. Patients who discontinued CLT (n = 29) or clopidogrel (n = 11) were interviewed within 18 months of hospitalization. Patients were recruited and interviewed until data saturation was achieved. The Health Belief Model was used as an organizing framework in analyzing and coding the narrative data. The codes were then summarized for each group and compared to identify similarities and differences in reasons for CLT and clopidogrel discontinuance. Results and Conclusions: The most common reason for CLT discontinuance was adverse effects that were painful and interfered with daily life. Less common reasons for discontinuance were prescription confusion, cost, mistrust in medicines/healthcare system, and preference for alternative therapies. Reasons for clopidogrel discontinuance were duration confusion, adverse effects, and cost. Although doctors stopped patients' clopidogrel in preparation for surgery, doctors conceded to discontinuance of CLT for patients who experienced adverse effects after trying 2 to 3 different CLTs. Patients who discontinued CLT were more likely to believe that they did not need the treatment than do patients who discontinued clopidogrel. Clinicians should be aware that reasons may vary across patients and medication class for prematurely stopping therapy; thus, proactive interventions should be targeted to address these differences. Identifying at-risk patients for targeted interventions to prevent premature cardiac medication discontinuation is vital.
- 1 March 2009
- Published by Elsevier in American Heart Journal
- Vol. 157 (3) , 556-562
Risk factor management after myocardial infarction: Reported adherence and outcomes
- 1 March 2009
- Published by Elsevier in American Heart Journal
- Vol. 157 (3) , 556-562
Risk factor management after myocardial infarction: Reported adherence and outcomes
- Open Access
- 31 December 2008
- Published by Springer Nature in Implementation Science
- Vol. 3 (1) , 58
Implementing an innovative consent form: the PREDICT experience
In the setting of coronary angiography, generic consent forms permit highly variable communication between patients and physicians. Even with the existence of multiple risk models, clinicians have been unable to readily access them and thus provide patients with vague estimations regarding risks of the procedure.
- 31 December 2008
- Published by Springer Nature in Implementation Science
- Vol. 3 (1) , 58
Open AccessImplementing an innovative consent form: the PREDICT experience
In the setting of coronary angiography, generic consent forms permit highly variable communication between patients and physicians. Even with the existence of multiple risk models, clinicians have been unable to readily access them and thus provide patients with vague estimations regarding risks of the procedure.
- Open Access
- 1 June 2008
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 2, 167-75
Clopidogrel-taking behavior by drug-eluting stent patients: Discontinuers versus continuers
Peer reviewed article authored by (Carole Decker, Linda Garavalia, Brian Garavalia, John A Spertus). Read article or submit your manuscript for publishing.
- 1 June 2008
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 2, 167-75
Open AccessClopidogrel-taking behavior by drug-eluting stent patients: Discontinuers versus continuers
Peer reviewed article authored by (Carole Decker, Linda Garavalia, Brian Garavalia, John A Spertus). Read article or submit your manuscript for publishing.
- 1 November 2007
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 22 (6) , 459-465
Acute Myocardial Infarction Patients' Information Needs Over the Course of Treatment and Recovery
Background and Research Objective: Healthcare guidelines promote including patients in healthcare decision making to optimize treatment and recovery. However, prior research varies widely in the clinical context and conceptualization of patient involvement. The current study focuses on describing cardiac patients' preferences for involvement in decision making in the context of the myocardial infarction event continuum. Subjects and Methods: Focus groups were conducted with 19 patients who had recently experienced a myocardial infarction and received care at a regional facility in the Midwest. Data were transcribed and analyzed qualitatively to identify themes related to patient's decision-making experiences. Results and Conclusions: Both the role of the patient in decision making and information needs change as the patient progresses from the acute event to recovery. However, this change seems to be curvilinear, rather than linear. To maximize outcomes, clinicians must assess preferences and increase awareness of evolving information needs throughout the myocardial infarction clinical situation.
- 1 November 2007
- Published by Wolters Kluwer Health in Journal of Cardiovascular Nursing
- Vol. 22 (6) , 459-465
Acute Myocardial Infarction Patients' Information Needs Over the Course of Treatment and Recovery
Background and Research Objective: Healthcare guidelines promote including patients in healthcare decision making to optimize treatment and recovery. However, prior research varies widely in the clinical context and conceptualization of patient involvement. The current study focuses on describing cardiac patients' preferences for involvement in decision making in the context of the myocardial infarction event continuum. Subjects and Methods: Focus groups were conducted with 19 patients who had recently experienced a myocardial infarction and received care at a regional facility in the Midwest. Data were transcribed and analyzed qualitatively to identify themes related to patient's decision-making experiences. Results and Conclusions: Both the role of the patient in decision making and information needs change as the patient progresses from the acute event to recovery. However, this change seems to be curvilinear, rather than linear. To maximize outcomes, clinicians must assess preferences and increase awareness of evolving information needs throughout the myocardial infarction clinical situation.